Abstract
Patients with chronic kidney disease (CKD) and ischemic heart disease (IHD) have strikingly high mortality rates. In the general population, there has been a reduction in the mortality and morbidity rates for IHD through the implementation of effective risk-factor-reduction programs and better interventions for patients with established IHD. No such trend has been observed in patients with end-stage kidney disease. This review article addresses the following topics: (i) epedemiology, pathogenesis, clinical CKD patients with IHD; (ii) diagnostic modalities for IHD and their limitation in CKD patients; (iii) medical treatment options and revascularization strategies for these high-risk patients; and (iv) optimal cardiovascular risk management. Generally, in CKD patients with IHD an aggressive approach to IHD is warranted, a low threshold for diagnostic testing should be employed, and awaiting a clinical trial targeting these patients they should be considered for all proven strategies to improve outcomes.
| Original language | English |
|---|---|
| Pages (from-to) | 219-231 |
| Number of pages | 13 |
| Journal | American Journal of Cardiovascular Drugs |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Alteplase, therapeutic use
- Anticoagulants, therapeutic use
- Antithrombotics, therapeutic use
- Aspirin, therapeutic use
- Beta adrenergic receptor antagonists, therapeutic use
- Cardiovascular disorders, prevention
- Clopidogrel, therapeutic use
Fingerprint
Dive into the research topics of 'Management of ischemic heart disease in patients with chronic kidney disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver